US FDA rejects Intarcia’s diabetes treatment implant | Boulder Peptide Symposium

September 15-18, 2025

LIVE, In Person at the St. Julien Hotel in Boulder, Colorado
The only conference focused solely on the pharmaceutical development of peptide therapeutics.
MENU

US FDA rejects Intarcia’s diabetes treatment implant

US FDA rejects Intarcia’s diabetes treatment implant
Peptide News from Biotech and Pharma, Raw News October 3, 2017

ITCA 650 is an implantable pump designed to deliver a continuous supply of the glucagon-like peptide-1 agonist exenatide, which is the active ...

Email

support@boulderpeptide.org

s2Member®
loading...